Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art

Taylor H. Schreiber, Luis Raez, Joseph D. Rosenblatt, Eckhard R Podack

Research output: Contribution to journalReview article

36 Scopus citations

Abstract

Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines.

Original languageEnglish (US)
Pages (from-to)105-112
Number of pages8
JournalSeminars in Immunology
Volume22
Issue number3
DOIs
StatePublished - Jun 1 2010

Keywords

  • Cancer
  • Immunosurveillance
  • Immunotherapy
  • Vaccine(s)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art'. Together they form a unique fingerprint.

  • Cite this